Elise A. Olsen, MD, FAAD, Editor

This issue brings together the experience of not only physician authors with direct expertise in the management of patients with cutaneous lymphoma but also those who have contributed to the recent advances in this area. Taken together, these articles cover the evaluation, diagnostic elements from both clinical and pathologic assessment, and staging/classification of all types of B-cell and T-cell cutaneous lymphoma. The entire spectrum of treatments utilized for MF and SS is given in individual articles, and separate articles on the treatment of the CD30+ lymphoproliferative disorders and cutaneous B-cell lymphoma give an overview on these other common types of cutaneous lymphoma.

On behalf of my coauthors, I hope that the information provided in this issue will accomplish several goals, the first of which is to update physicians on the advances in this area in the last decade. Since all current treatment for cutaneous lymphoma, regardless of subtype, is stage-based, it is important that those initially seeing these patients are aware of the nuances involved in staging and classification. In addition, this issue can serve as a ready resource of all the current treatment options for cutaneous lymphoma, particularly MF, including efficacy and safety information germane to clinical practice. In summary, if this is accomplished, then the lives of those with cutaneous lymphoma will be advanced.